MS and Demyelinating Disorders

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, discuss the prevelance of multiple sclerosis and comment on the mechanisms of action and available drug classes utilized in disease management.

Experts in neurology provide insight into the impact multiple sclerosis can have on patients and hypothesize about initiating treatment before cognitive impairment is observed.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, discuss the impact of polypharmacy on cognitive health and share their thoughts on deciding when to cease treatments in patients with multiple sclerosis.

CXCL2 and CXCL12, known to induce B-cell proliferation and differentiation, were significantly higher in those with acute and remitted cases of NMOSD compared with controls.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending August 20, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 19, 2022.

Data assessing samples of deep cervical lymph node aspirates and blood suggest that germinal center activity was associated with clinical relapses in individuals with neuromyelitis optica spectrum disorder.

Data suggest that long-term treatment with immunosuppression therapies, such as rituximab, is generally appropriate for patients with neuromyelitis optica, though transverse myelitis might indicate a higher risk of relapse post discontinuation.

The coauthors of a study assessing costs associated with unused disease-modifying therapies shared their insight into the extended effects of unused treatments in MS, including the importance of transparency between physician and patient. [WATCH TIME: 12 minutes]

Clene Nanomedicine’s gold nanocrystal suspension treatment showed significant improvements in Low Contrast Letter Acuity and Multiple Sclerosis Functional Composite scores among individuals with relapsing multiple sclerosis.

Drs Randall Schapiro and Jeffrey Wilken provide insight into the risk factors and disease progression noted in patients with multiple sclerosis.

Experts in neurology comment on the lack of definition of cognitive impairment in multiple sclerosis, highlighting an inability to adequately screen for and measure this disease symptom.

Here's some of what is coming soon to NeurologyLive® this week.

After failing to show statistical significance in a cohort of children, teriflunomide, the disease-modifying medication observed in the analysis, had compelling evidence to suggest it was efficacious in that age group following the Bayesian approach to analysis.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 12, 2022.

Drs Jeffrey Dunn and Regina Berkovich review available tools and resources for the care of patients with multiple sclerosis, focusing on specific symptoms.

Experts in neurology explore the benefits of a collaborative care approach for patients with multiple sclerosis.

Regina Berkovich, MD, PhD, shares her approach on the initiation and cessation of treatment for patients with multiple sclerosis who are considering family planning and vaccinations.

Experts in neurology share practice pearls to optimize the treatment for patients with multiple sclerosis.

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, share their excitement for the future of multiple sclerosis treatment and comment on emerging therapies.

Experts in neurology provide insight into treatment selection and sequencing in patients with multiple sclerosis, focusing on S1P modulators.

The coauthors of a study assessing costs associated with unused disease-modifying therapies shared their insight into the extended effects of unused treatments in MS. [WATCH TIME: 14 minutes]

The impact of retinal thinning was higher when using GCIPL rather than pRNFL thinning as it explained more of the variance in relapse remission.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, comment on early investigations surrounding the impact of multiple sclerosis on cognition and brain health and the current lack of focus regarding its impact on patients.

Ahmed Obeidat, MD, PhD; and Randall Schapiro, MD, FAAN, discuss the prevalence of multiple sclerosis and highlight how the disease has evolved since they began practicing. They also review the impact it has on patients and their support communities.

BPCLI was observed in both NMOSD and MOGAD but was relatively rarer in AQP4 NMOSD, with meningoencephalitis-like episodes among the sources of misdiagnosis.

Here's some of what is coming soon to NeurologyLive® this week.